Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JUNE 04, 2010 FBO #3114
SOLICITATION NOTICE

76 -- Online Web Access to Pharmaprojects Intelligence Database or Equal To Product

Notice Date
6/2/2010
 
Notice Type
Combined Synopsis/Solicitation
 
NAICS
511120 — Periodical Publishers
 
Contracting Office
Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
 
ZIP Code
20857-0001
 
Solicitation Number
FDA-SOL-10-1073224
 
Archive Date
6/26/2010
 
Point of Contact
Brendan McCarthy, Phone: 301-827-4680, Sherry Solodkova, Phone: 301-827-7165
 
E-Mail Address
Brendan.McCarthy@fda.hhs.gov, sherry.solodkova@fda.hhs.gov
(Brendan.McCarthy@fda.hhs.gov, sherry.solodkova@fda.hhs.gov)
 
Small Business Set-Aside
N/A
 
Description
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. This synopsis is to notify contractors that the government intends to issue a Purchase Order on a brand name or equal basis in accordance with FAR Part 13 for the following, under simplified acquisition procedures. The Request for Proposal number is FDA-SOL-10-1073224. Provisions and clauses in effect through Federal Acquisition Circular 05-37 are incorporated into this request. It is the contractor's responsibility to be familiar with the applicable clauses and provisions. The provisions and clauses may be accessed in full text at www.acquisition.gov/far. The NAICS code is 511120 Periodical Publishers. There is no set-aside for this acquisition. All qualified vendors are encouraged to submit a proposal. The purpose of this procurement is to establish a contract for 24/7 online web access to the Pharmaprojects intelligence database (brand name or equal to product) for one (1) base period and three (3) additional option periods. Each period will be twelve (12) months. Products shall support the FDA Biosciences Library and researchers assigned to all sites within the agency. The U.S. Food and Drug Administration request proposal responses from qualified sources capable of providing 24 hours a day, 7 days a week web access to Pharmaprojects database or equal to product. BASE PERIOD CLIN 0001- Online web access - Pharmaprojects intelligence database (brand name or equal to), Period of Performance: 12 months. OPTION PERIOD 1 CLIN 0002 - Online web access - Pharmaprojects intelligence database (brand name or equal), Period of Performance: 12 months. OPTION PERIOD 2 CLIN 0003 - Online web access - Pharmaprojects intelligence database (brand name or equal), Period of Performace: 12 months. OPTION YEAR 3 CLIN 0004 - Online web access - Pharmaprojects intelligence database (brand name or equal), Period of Performance: 12 months. Anticipated Base Year Period of Performance: June 1, 2010 - May 31, 2011 (plus 3, 12 month options). If not brand name as specified above, the proposed product shall meet the following Salient Characteristics: 1. The resource shall include reports on the progress of new pharmaceutical products, both new chemical entities and biotechnological entities, at all stages of development from early pharmaceutical studies to final launch in all major markets and cover discontinuation for whatever reason. 2. The Contractor shall provide 24/7 access for Agency staff via password/IP with unlimited access for 1-3 concurrent users. Passwords shall be automatically generated by Contractor (based on sign-up) for 1-3 concurrent user access. 3. The database shall include information related to new active substances dating back to the 1980's. 4. The resource shall have one (1) search platform offering a high level of functionality that includes the ability to perform complex searches linking together any of the seventy-five (75) searchable fields including specific drug protein target and target families. 5. The system shall contain Drug Profiles providing key data: therapies and indications by phase, originator and licenses, pharmacokinetic data, clinical trials data, and country information. 6. The database shall have search capability on Trend Analysis, Company, and Therapy Profile. The product shall also contain a chemical structure search where staff can search for drugs by exact, similar or substructure. 7. The resource shall have review incidence, prevalence, and market data for 218 drug therapeutic areas and shall have the ability to cutomize reports and graphs and export in a variety of formats. 8. The Contractor shall provide the FDA with access to an Editorial team that enables customers to make an unlimited number of research requests. 9. The product shall provide linking to SCRIP articles and information shall be updated on a weekly basis. 10. The Contractor shall provide usage statistics on a monthly basis. The format of the usage statistics shall be provided either via email or Contractor provided login and should include session count and user count when possible. 11. Product shall have the functional capability for users to conduct chemical structure searching and have access to research information for some 36,000 drugs. 12. Contractor shall provide online tutorials and/or a minimum of twenty (20)hours of web based training to end users in the Washington D.C. area as well as select remote offices as required. Web based support for end users shall also be provided. 13. This requirement is subject to Section 508 compliance. Vendor proposals shall address how the proposed solution will comply with Section 508. Specifically the following 508 Standards are applicable: 1194.22 Web-based intranet and internet information and applications; 1194.41 Information, documentation, and support. Evaluation Factors for Award: The Government shall award a contract resulting from this solicitation to the responsible offeror whose offer is the lowest price technically acceptable offer, which shall represent best value to the Government. Award will be made on the basis of the lowest evaluated price (inclusive of options) meeting or exceeding the non-cost factor (technical conformance to the requirements of the solicitation). The Government intends to evaluate offers and award a contract without discussions. The offeror's initial offer should contain the offeror's best terms from a price standpoint. However, the Government reserves the right to conduct discussions if later determined by the Contracting Officer to be necessary. The Government may reject any or all offers if such action is in the best interest of the Government; accept other than the lowest offer; and waive informalities and minor irregularities in offers received. Evaluation Factors for Award: Lowest price, Technically acceptable. Offerors shall price each CLIN (including options). This is an all or nothing requirement, therefore, vendor shall provide a price for each requirement with the CLINs, otherwise your proposal will be determined to be substantially incomplete and not warrant any further consideration. The following factors shall be used to evaluate offers: 1. Technical Features Meeting/Exceeding Salient Requirements (Brand Name or Equal) 2. Total Price (all CLINs shall be priced) Proposal Instructions to Offerors: Offerors are required to submit their proposals in two separate volumes as follows: Volume I - Technical Volume II - Pricing Proposal The completion and submission of the above items will constitute an offer (proposal) and will indicate the offeror's unconditional assent to the terms and conditions of this RFP and any attachments hereto. Alternate proposals are not authorized. Objections to any terms and conditions of the RFP will constitute deficiency, which may render the offer unacceptable. Volume I - Technical: This volume shall contain the Technical Approach. This portion of the proposal to include all data and information required for technical evaluation of brand name or equal product, and exclude any reference to the pricing aspects of each offer. If an equal product is proposed, offeror shall demonstrate how that product is equal to the brand name product. Offerors shall demonstrate in sufficient detail a technical approach that will successfully accomplish each of the requirements of the salient characteristics. For purposes of clarification for the Technical Evaluation Team, offerors are encouraged to provide trial access to their products to demonstrate how the requirements of the attached SOW are addressed and met. Volume II - Pricing: This volume shall include the complete pricing. Offerors shall propose pricing for a twelve (12) month base period with an option for three (3) additional 12 month periods. FAR Provisions & Clauses: FAR 52.203-6 ALT I, Restrictions on subcontractor Sales to the Government; FAR 52.211-6, Brand Name or Equal; FAR 52.212-1, Instructions to Offerors---Commercial Items, apply to this acquisition with the exception of (d), (h), and (i) of the clause, which are RESERVED; FAR 52.212-3, Offeror Representations and Certifications-Commercial Items; FAR 52.212-4, Contract Terms and Conditions---Commercial Items; FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items (Apr 2010). In compliance with said clause, the following FAR clauses apply: 52.219-4, Notice of Price Evaluation Preference for HUBZone Small Business Concerns; 52.222-3, Convict Labor; 52.222-19, Child Labor-Cooperation with Authorities and Remedies; 52.222-21, Prohibition of Segregated Facilities; 52.222-26, Equal Opportunity; 52.222-36, Affirmative Action for Handicapped Workers with disabilities; 52.225-13, Restrictions on Certain Foreign Purchases; 52.232-33, Payment by Electronic Funds Transfer-Central Contractor Registration (Oct 2003); FAR 52.213-2, Invoices Offerors are reminded to include a completed copy of 52.212-3 ALT I with their response, or provide an affirmative response that the offeror is registered in ORCA and all information in ORCA is current and complete. All clauses shall be incorporated by reference or full text in the order. Additional contract terms and conditions applicable to this procurement: 52.217-9 Option to Extend the term of the Contract (MAR 2000) (a) The Government may extend the term of this contract by written notice to the Contractor anytime within current period of performance; (b) If the Government exercises this option, the extended contract shall be considered to include this option clause; (c) The total duration of this contract, including the exercise of any options under this clause, shall not exceed 48 months. (End of clause) The contractor is requested to hold price quotations for a minimum of 45 days. Other Administrative Instructions: Central Contractor Registration (CCR). In accordance with FAR 52.212-4, Offerors shall be registered in the CCR database to be considered for award. Registration is free and can be completed on-line at http://www.ccr.gov; provide DUNS number; Cage Code and TIN. Proposals shall be submitted by email only as a MS Word or Adobe PDF attachment to Brendan McCarthy at brendan.mccarthy@fda.hhs.gov. Proposals are due by 3:00 pm Eastern Time on 11 June 2010. Any questions must be addressed to Brendan McCarthy, brendan.mccarthy@fda.hhs.gov/301-827-4680.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/FDA-SOL-10-1073224/listing.html)
 
Place of Performance
Address: Primary Site-, FDA BioSciences Library, WO2, Room 3051, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, United States
Zip Code: 20993
 
Record
SN02166611-W 20100604/100602235539-833c0b664884af6b058b89d91affc5ea (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.